| Study Name . | REGARD . | RAINBOW . | RAINFALL . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAM + BSC (n = 212) . | PBO + BSC (n = 99) . | RAM + PAC (n = 306) . | PBO + PAC (n = 285) . | RAM + CC (n = 279) . | PBO + CC (n = 283) . | |||||||
| Weight loss in C1, n (%) | 32 (≥3) | 180 (<3) | 13 (≥3) | 86 (<3) | 47 (≥3) | 259 (<3) | 45 (≥3) | 240 (<3) | 80 (≥3) | 199 (<3) | 81 (≥3) | 202 (<3) |
| Median OS, mo | 2.6 | 6.3 | 2.5 | 4.8 | 8.0 | 10.8 | 5.4 | 9.0 | 10.6 | 11.7 | 9.3 | 11.9 |
| Unadjusted HR (95% CI) | 0.361 (0.237–0.548) | 0.342 (0.185–0.633) | 0.707 (0.503–0.995) | 0.559 (0.398–0.784) | 0.880 (0.650–1.192) | 0.629 (0.467–0.848) | ||||||
| Adjusted HR a (95% CI) | 0.414 (0.268–0.639) | 0.341 (0.180–0.645) | 1.069 (0.726–1.574) | 0.763 (0.523–1.114) | 0.903 (0.664–1.229) | 0.690 (0.507–0.938) | ||||||
| Study Name . | REGARD . | RAINBOW . | RAINFALL . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAM + BSC (n = 212) . | PBO + BSC (n = 99) . | RAM + PAC (n = 306) . | PBO + PAC (n = 285) . | RAM + CC (n = 279) . | PBO + CC (n = 283) . | |||||||
| Weight loss in C1, n (%) | 32 (≥3) | 180 (<3) | 13 (≥3) | 86 (<3) | 47 (≥3) | 259 (<3) | 45 (≥3) | 240 (<3) | 80 (≥3) | 199 (<3) | 81 (≥3) | 202 (<3) |
| Median OS, mo | 2.6 | 6.3 | 2.5 | 4.8 | 8.0 | 10.8 | 5.4 | 9.0 | 10.6 | 11.7 | 9.3 | 11.9 |
| Unadjusted HR (95% CI) | 0.361 (0.237–0.548) | 0.342 (0.185–0.633) | 0.707 (0.503–0.995) | 0.559 (0.398–0.784) | 0.880 (0.650–1.192) | 0.629 (0.467–0.848) | ||||||
| Adjusted HR a (95% CI) | 0.414 (0.268–0.639) | 0.341 (0.180–0.645) | 1.069 (0.726–1.574) | 0.763 (0.523–1.114) | 0.903 (0.664–1.229) | 0.690 (0.507–0.938) | ||||||
a REGARD-adjusted by ECOG PS, peritoneal metastasis, location of primary tumor; RAINBOW-adjusted by region, ECOG PS, weight loss prior to enrollment, number of meta sites, ascites, tumor differentiation, and prior gastrectomy; RAINFALL-adjusted by region, ECOG PS, weight loss prior to enrollment, and peritoneal metastasis.
Abbreviations: BSC, best supportive care; C1, cycle 1; CC, cisplatin + capecitabine; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; PAC, paclitaxel; PBO, placebo; RAM, ramucirumab; OS, overall survival.
| Study Name . | REGARD . | RAINBOW . | RAINFALL . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAM + BSC (n = 212) . | PBO + BSC (n = 99) . | RAM + PAC (n = 306) . | PBO + PAC (n = 285) . | RAM + CC (n = 279) . | PBO + CC (n = 283) . | |||||||
| Weight loss in C1, n (%) | 32 (≥3) | 180 (<3) | 13 (≥3) | 86 (<3) | 47 (≥3) | 259 (<3) | 45 (≥3) | 240 (<3) | 80 (≥3) | 199 (<3) | 81 (≥3) | 202 (<3) |
| Median OS, mo | 2.6 | 6.3 | 2.5 | 4.8 | 8.0 | 10.8 | 5.4 | 9.0 | 10.6 | 11.7 | 9.3 | 11.9 |
| Unadjusted HR (95% CI) | 0.361 (0.237–0.548) | 0.342 (0.185–0.633) | 0.707 (0.503–0.995) | 0.559 (0.398–0.784) | 0.880 (0.650–1.192) | 0.629 (0.467–0.848) | ||||||
| Adjusted HR a (95% CI) | 0.414 (0.268–0.639) | 0.341 (0.180–0.645) | 1.069 (0.726–1.574) | 0.763 (0.523–1.114) | 0.903 (0.664–1.229) | 0.690 (0.507–0.938) | ||||||
| Study Name . | REGARD . | RAINBOW . | RAINFALL . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAM + BSC (n = 212) . | PBO + BSC (n = 99) . | RAM + PAC (n = 306) . | PBO + PAC (n = 285) . | RAM + CC (n = 279) . | PBO + CC (n = 283) . | |||||||
| Weight loss in C1, n (%) | 32 (≥3) | 180 (<3) | 13 (≥3) | 86 (<3) | 47 (≥3) | 259 (<3) | 45 (≥3) | 240 (<3) | 80 (≥3) | 199 (<3) | 81 (≥3) | 202 (<3) |
| Median OS, mo | 2.6 | 6.3 | 2.5 | 4.8 | 8.0 | 10.8 | 5.4 | 9.0 | 10.6 | 11.7 | 9.3 | 11.9 |
| Unadjusted HR (95% CI) | 0.361 (0.237–0.548) | 0.342 (0.185–0.633) | 0.707 (0.503–0.995) | 0.559 (0.398–0.784) | 0.880 (0.650–1.192) | 0.629 (0.467–0.848) | ||||||
| Adjusted HR a (95% CI) | 0.414 (0.268–0.639) | 0.341 (0.180–0.645) | 1.069 (0.726–1.574) | 0.763 (0.523–1.114) | 0.903 (0.664–1.229) | 0.690 (0.507–0.938) | ||||||
a REGARD-adjusted by ECOG PS, peritoneal metastasis, location of primary tumor; RAINBOW-adjusted by region, ECOG PS, weight loss prior to enrollment, number of meta sites, ascites, tumor differentiation, and prior gastrectomy; RAINFALL-adjusted by region, ECOG PS, weight loss prior to enrollment, and peritoneal metastasis.
Abbreviations: BSC, best supportive care; C1, cycle 1; CC, cisplatin + capecitabine; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; PAC, paclitaxel; PBO, placebo; RAM, ramucirumab; OS, overall survival.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
